Shares in blood products and flu vaccine business CSL Limited (ASX: CSL) hit another record high of $232.69 today thanks to the falling Australian dollar making its U.S. dollar profits more valuable to Australian investors.
The US dollar is now buying close to A$1.40 on the back of the diverging interest rate spreads between the two countries with expectations that the Aussie dollar may have further to fall.
CSL has plenty going for it without the free kick of a weaker Australian dollar, as it was recently reported that the group plans to double the size of some of its US flu vaccine outputs via its Sequiris business in FY 2019 after gaining regulatory approval from the FDA.
Fresh from growing profits 29% in FY 2018, CSL is now forecasting profit growth of 10% – 14% in FY 2019, which is impressive considering it’s no tiddler.
In fact with a market value over $103 billion it’s only behind BHP Billiton Limited (ASX: BHP) and the Commonwealth Bank of Australia (ASX: CBA) in terms of market size. It might even overtake these two in the five years ahead if its earnings growth trajectory continues.
Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading over 40% off it's high, all while offering a fully franked dividend yield over 3%...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
Motley Fool contributor Tom Richardson owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.